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Abstract
Heat shock protein 90 (Hsp90) is a significant target in the development of rational cancer therapy due to its role at the
crossroads of multiple signaling pathways associated with cell proliferation and cell viability. The relevance of Hsp90 as
a therapeutic target for numerous diseases states has prompted the identification and optimization of novel Hsp90
inhibitors as an emerging therapeutic strategy. We performed a screening aimed to identify novel Hsp90 inhibitors among
several natural compounds and we focused on the iminosugar (+)-lentiginosine, a natural amyloglucosidases inhibitor, for
its peculiar bioactivity profile. Characterization of Hsp90 inhibition was performed using a panel of chemical and biological
approaches, including limited proteolysis, biochemical and cellular assays. Our result suggested that the middle domain of
Hsp90, as opposed to its ATP-binding pocket, is a promising binding site for new classes of Hsp90 inhibitors with multi-
target anti-cancer potential.
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Introduction
Heat shock protein 90 (Hsp90) is an abundant molecular
chaperone involved in a variety of cellular processes ranging
from signal transduction to viral replication. Hsp90 is involved
in the folding, stabilization, activation and assembly of a wide
range of ‘‘client’’ proteins, thus playing a central role in many
cellular processes [1]. Since multiple oncogenic proteins are
substrates for the Hsp90 mediated protein folding process, this
molecular chaperone has emerged as an exciting target for the
development of cancer chemotherapeutics. In addition, studies
suggested that certain Hsp90 inhibitors accumulate in tumor
cells more effectively than in normal tissue, leading to .200
fold differential selectivity [2]. Coupled with the observation
that Hsp90 is over-expressed in a variety of human malignan-
cies, the development of Hsp90 inhibitors has become an
attractive chemotherapeutic approach [3–8]. To date, many
clinical and translational researches on Hsp90 inhibitors have
been based on gendanamycin derivatives, such as 17-allylamino-
17-demethoxygeldanamycin (17-AAG) or 17-dimethylaminoethy-
lamino-17-demethoxygeldanamycin (17-DMAG). Some difficul-
ties encountered clinically with these inhibitors include hepatic
toxicity and drug administration through intravenous infusion
[9]. These issues highlight a critical need for novel and
improved inhibitor. Medicinal plants and their active metabo-
lites are one of the major sources of chemical diversity for
starting materials in drug discovery for the treatment of human
diseases including cancer [10,11]. Such medicinal plants often
contain small alkaloids as the active principles, which have the
advantage of being orally available [12].
On this basis, we performed a screening oriented to obtain
Hsp90 inhibitors on several natural compounds and we focused on
the iminosugar (+)-lentiginosine for its chemical and bioactivity
characteristics. (+)-Lentiginosine, a natural occurring dihydrox-
yindolizidine alkaloid, has been shown to be a selective and the
most powerful indolizidine inhibitor of amyloglucosidases [13,14].
Besides, recently the synthetic enantiomer (2)-lentiginosine was
found a proapoptotic inducer with low cytotoxicity [15,16].
Herein we report the study of Hsp90 inhibitory activity of (+)-
lentiginosine and some its synthetic derivatives, performed by
means of a panel of chemical and biological approaches. Our
results demonstrated that in vitro (+)-lentiginosine represent an
innovative scaffold for the design of new Hsp90 inhibitors
interacting with the protein middle domain. Since glycosidase
inhibitors have received growing attention as potential therapeutic
agents for several pathologies, also including tumor metastasis
[17–19], the anti-Hsp90 effects of (+)-lentiginosine, together with
its anti-amyloglucosidases activity could indicate this compound as
a very interesting lead for the design of a new class of
multifunctional inhibitors.
Results and Discussion
In order to evaluate the ability of iminosugars to affect the
biological activity of Hsp90, we started a chemical-biological study
using (+)-lentiginosine (compound 1 in Figure 1) as model
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compound; it was selected because of its simple structure, high
water solubility, and significant biological activity [13,14].
As a first step, we evaluated of the ability of compound 1 to
interact with Hsp90 by a surface plasmon resonance (SPR) based
binding assay; some lentiginosine synthetic derivatives [20,21]
including the enantiomer (2)-lentiginosine (compounds 2–7,
Figure 1), were also tested. Radicicol [22] was used as positive
controls. This assay allowed us to verify the affinity of compounds
1–7 toward the investigated protein, giving a detailed view about
their interaction with Hsp90 (Figure 2). Six out of the seven tested
compounds efficiently interacted with the immobilized protein, as
demonstrated by the concentration dependent responses, and by
the clearly discernible exponential curves, during both the
association and dissociation phases (Figure 2A). Only (-)-lentigi-
nosine did not bind to the molecular chaperone (Figure 2B).
Compounds 1–7 were also injected on immobilized bovine serum
albumin (BSA) to evaluate possible unspecific bindings, and they
did not interact with this protein.
Sensorgrams acquired for those compounds interacting with
Hsp90 were fitted to a single-site bimolecular interaction model
(A+B = AB): using this approach, kinetic and thermodynamic
parameters for each complex formation were achieved (Table 1).
Each constant was calculated fitting at least 12 curves, obtained by
injecting three times the investigated iminosugars at four different
concentrations, ranging from 0.020 mM to 1 mM. (+)-Lentigino-
sine (1) and compound 4 showed the higher affinity towards the
chaperone, as inferred by the 24.7 nM and 45.9 nM KD, measured
for the interaction of these compounds with Hsp90. Interestingly,
compounds 1, 3–6 showed very similar kinetic dissociation
constants (koff), thus suggesting that the modification made on
the (+)-lentiginosine structure did not affect the stability of the
complex with Hsp90, but sensibly lowered the complex formation
kinetic. On the basis of SPR data some activity-structure
relationship evaluations can be attempted: in particular, the
introduction of a partially hydrophobic portion resulted the most
efficient change of (+)-lentiginosine structure, whereas the hydro-
philic harms present in compounds 3 and 5 reduced affinity
towards Hsp90. This effect was confirmed by the results achieved
for compound 7, indicating that the introduction of a primary
amino group on C-7 of (+)-lentiginosine worsened both kinetic and
thermodynamic of its interaction with Hsp90.
To evaluate the effect of interacting compounds on Hsp90
biological activity, the ATPase activity of the enzyme was tested in
the presence of the most affine compounds (1, 3 and 4); as positive
controls we selected radicicol and 17-AAG, two of the most potent
inhibitors of the ATPase activity of the chaperone [23]. (2)-
Lentiginosine was used as negative control. The obtained results
(Figure 3) demonstrated that compounds 1, 3 and 4 inhibit the
ATPase activity of Hsp90 in a concentration dependent manner
and the efficiency of these compounds was in agreement with their
affinity towards the chaperone, as measured by SPR. Moreover,
compound 1 showed an inhibitory power higher than that
measured for 17-AAG.
The ability of compounds 1, 3 and 4 to inhibit the chaperone
activity of Hsp90 was also evaluated monitoring the citrate
synthase (CS) thermal induced aggregation in the presence of
Hsp90 [24], with or without these compounds. Again, radicicol
and compound 2 were used as positive and negative controls,
respectively (Figure 4). Upon incubation at elevated temperatures,
CS underwent quantitative aggregation, but the presence of
stoichiometric amounts of Hsp90 significantly changed the protein
aggregation kinetics. When a 4-fold molar excess of 1 was added to
this mixture, the curve slope increased becoming almost compa-
rable to that observed without the chaperone, confirming the
inhibition of Hsp90 chaperone activity by this compound. Similar
results were achieved with 3 and 4, even if their inhibitory effects
were less evident. The addition of the same amount of 2 did not
perturb the CS+Hsp90 curve, thus indicating that this compound
is not able to inhibit the chaperone activity of Hsp90.
Since unmodified (+)-lentiginosine showed the higher affinity
towards the chaperone and turned to be the most efficient
inhibitor of its ATPase activity, we focused our attention on the
mechanism of action of this compound. In an effort to identify the
Hsp90 region involved in (+)-lentiginosine binding, we first
performed some fluorescence polarization assays using a fluores-
cent geldanamycin probe (fGDA) to evaluate if this compound
could interact with the ATP-binding pocket of Hsp90 [25]. In our
experiments, compound 1 was unable to displace fGDA at
concentration up to 100 mM, independently if it was added before
or after fGDA addition; this result suggested that compound 1 acts
on Hsp90 by a mechanism different from that of the currently
available N-terminal inhibitors.
We used limited proteolysis-mass spectrometry based strategy
for the structural analysis of the Hsp90/1 complex. This
approach is based on the evidence that exposed, poorly
Figure 1. Structure of compounds 1–7.
doi:10.1371/journal.pone.0043316.g001
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structured, and flexible regions of a protein can be recognized
by a proteolytic enzyme. The differences in the proteolytic
patterns observed in presence or in absence of putative protein
ligands can be analyzed to identify the protein regions involved
in the molecular interactions [26]. The efficiency of this
approach in investigation of Hsp90/inhibitor complexes was
recently demonstrated [25]. The differences in proteolytic
patterns observed on Hsp90 or on Hsp90/1 complex
(Figure 5) confirmed a direct interaction occurring between
(+)-lentiginosine and the chaperone in free native state, and
demonstrated that Arg279, Lys336 and Lys366, hydrolyzed in
the experiments performed on the isolated protein, were
Figure 2. SPR analysis results. Sensorgrams obtained by injecting different concentrations (from 0.020 to 1 mM) of 1 (A), 2 (B), 3 (C), 4 (D), 5 (E), 6
(F) 7 (G) and radiciol (H) on immobilized Hsp90.
doi:10.1371/journal.pone.0043316.g002
(+)-Lentiginosine Inhibits Hsp90
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protected in the complex, suggesting an interaction mainly
involving the Hsp90 middle domain.
In order to describe at atomic level the molecular interactions
between the (+)-lentiginosine (1) and the (2)-lentiginosine (2) with
Hsp90, we performed docking calculations using Autodock Vina
[27] and Autodock 4.2 software [28]. For our studies we referred
to a crystal structure of the yeast middle and C-terminal domain
determined by Ali et al. in 2006 [29], used by us [30] and other
research groups [31], and its sequence alignment with the human
protein reported by Lee et al. [32] for the studies of new Hsp90
inhibitors. During our studies, we considered the lentiginosine
octahydro-indolizine ring protonated at physiological pH. Prior to
the docking calculations, we performed a conformational search
by means of molecular dynamics at different temperatures (300
and 750 K) and by Monte Carlo Method using the OPLS [33]
force field included in the MacroModel software package [34]. As
shown in Figure 6A, both 1 and 2 are able to interact with the
middle-domain of Hsp90, establishing hydrophobic interactions
and hydrogen bonds with protein side-chains (Lys337, Phe329,
Pro328). The similar h-bonds in the models Hsp90/1 and Hsp90/
2 were observed, between the OH at C-1 for both 1 and 2 with the
Lys366 and Asn340, whereas their cyclic portion are located on
opposite sides of the receptor surface hydrophobic pocket. On the
other hand, only the OH at C-2 of 1 is able to establish a further
hydrogen bond with Lys338.
Besides, our docking calculations showed a different spatial
arrangement of 1 and 2 around the amino acid Arg279
(Figure 6B), identified as involved in the inter-molecular in-
teraction by the MS experiments. In particular, even if both the
molecules form a hydrogen bond with this key amino acid, 1 forms
further and specific hydrogen bond with Lys274 and establishes
a hydrophobic contact with Asn280. Thus, the results of docking
calculations supported the view that (+)-lentiginosine preferentially
interacts with the middle domain, as previously disclosed by MS
analysis.
The higher number of hydrophobic and hydrogen bond
interactions of 1 with respect to 2 is in agreement with SPR
results, and suggest that these contacts may be critical for the
different ability in the modulation of the biological activity of
Hsp90 showed by these molecules. Our results indicated that (+)-
lentiginosine modulates Hsp90 action by affecting its ATPase
activity, even if it does not directly interact with the ATP binding
site. Indeed, our limited proteolysis and docking data indicated
that (+)-lentiginosine binds Hsp90 middle domain. This result is
not surprising since structural studies performed on Hsp90 by
different approaches demonstrated that intra-domain and inter-
domain interactions cooperatively stabilize the active conforma-
tion of Hsp90 ATPase active site [35]. Specifically, Hsp90 middle
domain indirectly and directly participates in the ATP hydrolysis:
the co-chaperones Aha-1 binds the Hsp90 middle domain and
modulated the ATPase activity of the enzyme [36]; besides, a loop
involving residues 376–380 stabilize the ATP binding site, both by
hydrophobic interaction and by the direct linkage between Arg380
and the c-phosphate of bound ATP [35]. Moreover, most of the
client and co-chaperones interact with the middle domain of
Hsp90 [7,8], and the binding of (+)-lentiginosine to that protein
region could also mask residues playing a critical role in the
Table 1. Thermodynamic and kinetic constants measured by
SPR for the interaction between tested compounds and
immobilized HSP90.
Compound KD (nM) koff (1/s)610
3
1 24.760.6 1.8660.31
2 No binding
3 108.361.1 2.1860.23
4 45.960.5 2.0560.42
5 115.661.6 2.5560.35
6 306.862.9 4.1260.81
7 1009.465.8 25.662.1
Radicicol 1.760.4 0.1560.03
doi:10.1371/journal.pone.0043316.t001
Figure 3. Inhibition of the ATPase activity of Hsp90 by different concentration of compounds 1–4. Radicicol and 17-AAG were used as
positive controls. Data are the mean of two independent experiments performed in triplicate and were analyzed by t test (Hsp90 vs Hsp90+ testing
compound): *P,0.05, **P,0.005.
doi:10.1371/journal.pone.0043316.g003
(+)-Lentiginosine Inhibits Hsp90
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recognition of substrates. From our data it can therefore be
deduced that the binding of (+)-lentiginosine to Hsp90 affects some
inter-domain interactions, resulting in a sensible decrease in the
activity of the chaperone.
The anti-Hsp90 effects of (+)-lentiginosine, together with its
anti-amyloglucosidases activity could therefore indicate this
compound as a very interesting lead for the design of a new class
of multifunctional inhibitors. Moreover, the selective binding to
Hsp90 of (+)-lentiginosine with respect to (–)-lentiginosine suggests
this compound as an useful probe to perform further conforma-
tional studies on the Hsp90 middle domain. Indeed, the middle
domain of Hsp90, as opposed to its ATP-binding pocket, appears
to be a promising binding site for Hsp90 client selective inhibitors
(30). Further studies on the interaction of the other compounds (3–
7), which showed a binding with the chaperone, will allow a better
definition of the interaction surface on the Hsp90 middle domain,
and to design new more active compounds.
Materials and Methods
General Procedures
MALDITOF/MS spectra were acquired by a MALDI micro
MX (Waters); SPR analyses were performed using a Biacore 3000
optical biosensor equipped with research-grade CM5 sensor chips
(GE Healthcare, Milano, Italy). Light scattering measurements
were performed with a Perkin Elmer LS 55 fluorimeter (Perkin
Elmer, Zaventem, Belgium) equipped by a water thermostatable
cell holder with stirrer.
Materials. Compounds 1–7 were synthesized according to
the literature [20,21]. Solvents (HPLC grade) were purchased
from Romil (ROMIL Ltd, Cambridge, UK). All buffers were
prepared with a Milli-Q water system (Millipore, Bedford, MA,
USA). Recombinant human Hsp90 and yeast Hsp82, provided by
Assay Designs (Ann Arbor, MI, USA), were cloned from a HeLa
cDNA library and expressed in E. coli and purified by multi-step
chromatography. Proteomic grade trypsin was purchased from
Sigma-Aldrich (Sigma-Aldrich Co, Milano, Italy).
Surface plasmon resonance analyses. SPR analyses were
performed as describe elsewhere [37,38]. Briefly, SPR analyses
were performed using a Biacore 3000 optical biosensor equipped
with research-grade CM5 sensor chips (GE Healthcare). Using this
platform, two separate recombinant Hsp90 surfaces, a BSA
surface and an unmodified reference surface were prepared for
simultaneous analyses. Proteins (100 mg mL21 in 10 mM sodium
acetate, pH 5.0) were immobilized on individual sensor chip
surfaces at a flow rate of 5 mL min21 using standard amine-
coupling protocols to obtain densities of 8–12 kRU. Compounds
1–7, as well as radicicol used as positive controls, were dissolved in
100% DMSO to obtain 4 mM solutions, and diluted 1:200 (v/v)
in PBS (10 mM NaH2PO4, 150 mM NaCl, pH 7.4) to a final
DMSO concentration of 0.5%. Compounds concentration series
were prepared as twofold dilutions into running buffer: for each
sample, the complete binding study was performed using a six-
Figure 4. Aggregation kinetics of CS at 43uC determined by light scattering. The spontaneous aggregation of CS at 43uC (¤) and the
aggregation of CS at 43uC in the presence of 0.075 mM Hsp90 (D) or of 0.075 mM Hsp90 and 0.3 mM compound 1 (&), 0.3 mM compound 2 (N), 0.3
compound 3 (%), or 0.3 mM compound 4 (#) are shown.
doi:10.1371/journal.pone.0043316.g004
Figure 5. Schematic representation of the results obtained
from limited proteolysis experiments. The preferential cleavage
sites detected on recombinant Hsp90, and on the Hsp90/1 complex are
in black. The Hsp90 N-terminal domain is highlighted in light grey, the
middle domain is boxed and the C-terminal domain is highlighted in
grey.
doi:10.1371/journal.pone.0043316.g005
(+)-Lentiginosine Inhibits Hsp90
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point concentration series, typically spanning 0.025–1 mM, and
triplicate aliquots of each compound concentration were dispensed
into single-use vials. Included in each analysis were multiple blank
samples of running buffer alone. Binding experiments were
performed at 25uC, using a flow rate of 50 mL min21, with 60 s
monitoring of association and 200 s monitoring of dissociation.
Simple interactions were adequately fit to a single-site bimolecular
interaction model (A+B = AB), yielding a single KD. Sensorgram
elaborations were performed using the Biaevaluation software
provided by GE Healthcare.
ATP Hydrolysis Inhibition
The Discover RX ADP HunterTM Plus Assay kit was used
following the manufacturer’s instructions. ATPase reactions were
carried out for 60 min at 40uC temperature in 100 mM Tris
pH 7.4, 100 mM ATP and 40 nM Hsp90 in presence of different
concentrations of compounds 1–4 or radicicol. ADP generation
was measured using a Perkin Elmer LS 55 fluorimeter (540 nm
excitation and 620 nm emission). Fluorescence intensity values
measured for Hsp90 without any testing compound was assumed
as 100% of enzyme activity. The background reaction rate was
measured in a reaction lacking enzyme or substrate and subtracted
from the experimental rates.
Citrate synthase aggregation assay. Chaperone activity
was evaluated as reported elsewhere by monitoring the thermal-
induced aggregation of Citrate synthase (CS) in absence or in
presence of a stoichiometric amount of Hsp90, and with or
without a 4-fold molar excess of each testing compound.
Aggregation was initiated by unfolding CS (0.075 mM) incubating
the protein in 40 mM HEPES–KOH, pH 7.5 at 43uC. Aggrega-
tion was monitored by measuring light scattering at right angles
with Perkin Elmer LS 55 fluorimeter in stirred and thermostated
quartz cells. Both the emission and excitation wavelengths were set
at 500 nm, and the band pass was 2 nm. Kinetics traces reported
here are the averages of two measurements.
Statistical Analysis
All the reported values represent the mean6standard deviation
(SD) of at least two independent experiments performed in
triplicate. Where necessary, data were statistically compared by t-
test.
Fluorescence polarization assay. Binding of compound 1
to human full length recombinant Hsp90 was determined by
a competitive binding fluorescence polarization assay using
a fluorescent geldanamycin probe, as reported elsewhere [25].
Limited proteolysis. Limited proteolysis experiments were
performed on recombinant Hsp82 at 37uC, PBS 0.1% DMSO,
using trypsin as proteolytic agent; 30 mL of a 3 mM Hsp90 solution
were used for each experiment. Binary complex Hsp90/1 was
formed by incubating the protein with a 5:1 molar excess of the
inhibitor at 37uC for 15 min prior to proteolytic enzyme addition.
Both protein and complex were digested using a 1:100 (w/w)
enzyme to substrate ratio. The extent of the reactions was
monitored on a time-course basis by sampling the incubation
mixture after 5, 15, and 30 min of digestion. Samples were
analyzed by MALDITOF/MS using a MALDI micro MX
(Waters). Mass data were elaborated using the Masslynx software
(Waters). Preferential hydrolysis sites on Hsp90 under different
conditions were identified on the basis of the fragments released
during the enzymatic digestions.
Computational Details
Molecular dynamics and Monte Carlo calculations were both
performed on (+)-lentiginosine (1) and (2)-lentiginosine (2) on a 46
AMD Opteron SixCore at 2.4 GHz. Molecular dynamics
calculations for both 1 and 2 were performed at two different
temperatures (300 and 750 K for 8 ns using 1.5 fs as time-step)
using the OPLS [33] force field (MacroModel software package)
[34]. During the calculations, a standard constant temperature
velocity2Verlet algorithm was used to integrate the equations of
motions [39]. All the obtained structures (numbering of 150,
selected at regular intervals throughout the simulation) from
Molecular Dynamics calculations for each isomer were minimized
using the Polak-Ribier conjugate gradient algorithm (PRCG,
100000 steps, convergence threshold 0.005 kJ mol21 A˚21), leading
to the selection of the lowest energy minimum conformer for both
the enantiomers. The distribution of the resulting geometries were
in accordance with the results of a parallel conformational search
performed with the Monte Carlo multiple minimum (MCMM)
method (OPLS, 10000 steps, numbering 150, stored on a similarity
and an energy criterion), where the variables used for the
calculations included all the possible rotatable torsions.
Figure 6. Docking calculation results. Three dimensional models (A and B) of (+)-lentiginosine (1, yellow) and (2)-lentiginosine (2, green) with
HSP90. The target molecule is depicted by sky blue ribbon and the crucial amino acids by cpk (by atom type: C, purple; O, red; N, dark blue, H, white).
doi:10.1371/journal.pone.0043316.g006
(+)-Lentiginosine Inhibits Hsp90
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We performed molecular docking experiments by Autodock 4.2
software [28] on 46AMD Opteron SixCore at 2.4 GHz. We used
a grid box size of 58622620 and 40624638 for chain A of Hsp82
(pdb code:2CGE) [29] with spacing of 0.375 A˚ between the grid
points, and centered at 258.992 (x), 33.009 (y), 1.978 (z), and at
280.075 (x), 19.979 (y), 6.43 (z). To achieve a representative
conformational space during the docking studies and for taking
into account the variable number of active torsions, 10 calculations
consisting of 256 runs were performed, obtaining 2560 structures
for each ligand. The Lamarckian genetic algorithm (LGA) was
employed for docking experiments, choosing an initial population
of 600 randomly placed individuals. The maximum number of
energy evaluations and of generations was set up to 56106 and to
66106 respectively. For all the docked structures, all bonds were
treated as active torsional bonds except the bonds in cycles, which
are considered fixed together with the receptors. Results differing
by less than 3.5 A˚ in positional root-mean-square deviation
(RMSD) were clustered together and represented by the result
with the most favorable free energy of binding. Moreover, we
complementarily used the Autodock Vina software [27] choosing
a grid box size of 28614612 and of 16610620, with spacing of
1.000 A˚ between the grid points, and centered258.717 (x), 29.973
(y) and 1.927 (z), and 280.075 (x), 19.979 (y) and 6.43 (z) covering
the two possible ligand binding site on the middle domain. For the
docking studies, we used an exhaustiveness of 512 with maximum
energy difference of 3 kcal/mol between the best binding mode
and the worst one displayed.
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